Physician profile
Grace Eizabeth Dunn
NPI 1003009853
$741.08
in general payments reported to CMS, 2019-2025
15 companies · $152 in 2025
The $152 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $158 · 2020: $26.23 · 2021: $33.25 · 2022: $24.49 · 2023: $139 · 2024: $208 · 2025: $152.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $499.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $111.27 | 2020-2025 | Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $101.64 | 2019-2025 | Bexsero, Shingrix, Pediarix |
| Abbvie INC. | $88.65 | 2023-2024 | Vraylar |
| Boston Scientific Corporation | $84.73 | 2024-2025 | Wavewriter Alpha Prime 16 |
| Sanofi Pasteur INC. | $76.15 | 2019-2021 | |
| Acadia Pharmaceuticals INC | $49.30 | 2025 | Daybue |
| Novo Nordisk INC | $39.52 | 2019-2025 | Ozempic, Rybelsus |
| Exact Sciences Corporation | $39.03 | 2024 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $29.67 | 2019 | |
| Astellas Pharma US INC | $24.45 | 2024 | Veozah |
| E.R. Squibb & Sons, L.L.C. | $22.09 | 2019 | |
| Inspire Medical Systems, INC. | $21.43 | 2024 | Inspire |
| Pfizer INC. | $19.61 | 2023 | |
| Seqirus USA INC | $17.93 | 2025 | Fluad, Flucelvax |
| Astrazeneca Pharmaceuticals Lp | $15.61 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Grace Dunn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.